本文仅供中国大陆地区执业的医学药学专业人士参考，如您非前述专业人士，请离开本页面
✩ 本文仅供医疗卫生等专业人士参考
*此文仅用于向医疗卫生专业人士提供科学信息，不代表平台立场
内容策划：郭青青
内容审核：林斌
参考文献
[1] Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):19-34.
[2] 中华医学会骨科分会关节外科学组, 中国医师协会运动医学医师分会, 海军军医大学附属长海医院. 中轴型脊柱关节炎诊断和治疗专家共识(2023年版)[J]. 中华关节外科杂志(电子版), 2023, 17(02): 151-160.
[3] Liu X, Wang Y, Chen W, et al. Work Productivity Is Associated with Disease Activity and Functional Ability in Chinese Patients with Axial Spondyloarthritis Using a Smart-Phone Management System: A Prospective Cohort Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10).
[4] 国家皮肤与免疫疾病临床医学研究中心（北京协和医院）, 中国医师协会风湿免疫专科医师分会, 中国康复医学会风湿免疫专业委员会, 等. 脊柱关节炎靶向药物治疗专家共识 [J] . 中华内科杂志, 2023, 62(6) : 606-618.
[5] McGonagle D, Aydin SZ, Marzo-Ortega H, et al. Hidden in plain sight: Is there a crucial role for enthesitis assessment in the treatment and monitoring of axial spondyloarthritis? Semin Arthritis Rheum. 2021 Dec;51(6):1147-1161.
[6] Schett G, Lories RJ, D'Agostino MA, et al. Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol. 2017 Nov 21;13(12):731-741.
[7] Mease PJ, Liu M, Rebello S, et al. Characterization of Patients With Axial Spondyloarthritis by Enthesitis Presence: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. ACR Open Rheumatol. 2020 Jul;2(7):449-456.
[8] Rademacher J, Poddubnyy D, Pleyer U. Uveitis in spondyloarthritis. Therapeutic Advances in Musculoskeletal Disease. 2020;12.
[9] Biggioggero M, Crotti C, Becciolini A, et al. The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future. Biomed Res Int. 2018 Oct 14;2018:9460187.
[10] López-Medina C, Molto A, Claudepierre P, et al. Clinical manifestations, disease activity and disease burden of radiographic versus non-radiographic axial spondyloarthritis over 5 years of follow-up in the DESIR cohort. Ann Rheum Dis. 2020 Feb;79(2):209-216.
[11] Kieskamp S, Wilbrink R, Wink F, et al. Radiographic Sacroiliitis Progression up to Six Years of Follow-Up in Patients with Non-Radiographic Axial Apondyloarthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9).
[12] 全国卫生产业企业管理协会风湿病与分子免疫分会.中轴型脊柱关节炎身体功能和健康生活质量综合评估的中国专家共识[J].中华医学杂志,2022,102(35):2755-2762.
[13] Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018 Apr;77(4):523-532.
[14] Shah M, Maroof A, Gikas P, et al. Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells. RMD Open. 2020 Jul;6(2):e001306.
[15] Mease, P.J., et al., Bimekizumab Improves Key Patient Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain and Fatigue: Results from Two Phase 3 Studies. ABSTRACT SUPPLEMENT ACR Convergence 2022, November 10–14, 2022, Philadelphia, PA, 2022. 74(Suppl. 9).
[16] van der Heijde D, Deodhar A, Baraliakos X, et al. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Ann Rheum Dis. 2023 Apr;82(4):515-526.
[17] Baraliakos X, Deodhar A, van der Heijde D, et al. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies. Ann Rheum Dis. 2024 Jan 11;83(2):199-213.
[18] Marina Nighat Magrey, et al. Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies. 2023 ACR ABSTRACT NUMBER: 0525.
[19] Deodhar A, Machado PM, Mørup M, et al. Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis. Rheumatology (Oxford). 2024 May 2;63(5):1195-1205.
